Shatnawi A - Search Results

1

ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer.

Shatnawi A, Ayoub NM, Alkhalifa AE. Shatnawi A, et al. Clin Breast Cancer. 2021 Aug;21(4):e319-e331. doi: 10.1016/j.clbc.2020.11.011. Epub 2020 Nov 19. Clin Breast Cancer. 2021. PMID: 33334698

2

Molecular and genetic crosstalks between mTOR and ERRα are key determinants of rapamycin-induced nonalcoholic fatty liver.

Chaveroux C, Eichner LJ, Dufour CR, Shatnawi A, Khoutorsky A, Bourque G, Sonenberg N, Giguère V. Chaveroux C, et al. Among authors: shatnawi a. Cell Metab. 2013 Apr 2;17(4):586-98. doi: 10.1016/j.cmet.2013.03.003. Cell Metab. 2013. PMID: 23562079 Free article.

3

Identification of the inhibitor of growth protein 4 (ING4) as a potential target in prostate cancer therapy.

Shatnawi A, Malkaram SA, Fandy T, Tsouko E. Shatnawi A, et al. Mol Cell Biochem. 2020 Jan;464(1-2):153-167. doi: 10.1007/s11010-019-03657-x. Epub 2019 Nov 27. Mol Cell Biochem. 2020. PMID: 31773467

4

Roles of the tumor suppressor inhibitor of growth family member 4 (ING4) in cancer.

Shatnawi A, Abu Rabe DI, Frigo DE. Shatnawi A, et al. Adv Cancer Res. 2021;152:225-262. doi: 10.1016/bs.acr.2021.05.004. Epub 2021 Jul 1. Adv Cancer Res. 2021. PMID: 34353439 Review.

5

Shatnawi A, Ayoub NM, Alkhalifa AE, Ibrahim DR. Shatnawi A, et al. Breast Cancer (Auckl). 2022 Mar 24;16:11782234221086713. doi: 10.1177/11782234221086713. eCollection 2022. Breast Cancer (Auckl). 2022. PMID: 35359609 Free PMC article.

6

BRAF Expression and Copy Number Alterations Predict Unfavorable Tumor Features and Adverse Outcomes in Patients With Breast Cancer.

Alhamdan YR, Ayoub NM, Jaradat SK, Shatnawi A, Yaghan RJ. Alhamdan YR, et al. Among authors: shatnawi a. Int J Breast Cancer. 2024 May 30;2024:6373900. doi: 10.1155/2024/6373900. eCollection 2024. Int J Breast Cancer. 2024. PMID: 38919805 Free PMC article.

7

The Clinicopathological and Prognostic Significance of the Expression of PD-L1 and MET Genes in Breast Cancer: Potential Therapeutic Targets.

Al-Diabat M, Ayoub NM, Al-Eitan L, Alshorman M, Shatnawi A. Al-Diabat M, et al. Among authors: shatnawi a. Curr Cancer Drug Targets. 2024 Oct 10. doi: 10.2174/0115680096333231240902070108. Online ahead of print. Curr Cancer Drug Targets. 2024. PMID: 39390836

8

A qualitative assessment of West Virginia pharmacist activities and attitude in diabetes management.

Shatnawi A, Latif DA. Shatnawi A, et al. J Eval Clin Pract. 2017 Jun;23(3):586-592. doi: 10.1111/jep.12677. Epub 2016 Nov 24. J Eval Clin Pract. 2017. PMID: 27882650

9

Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.

Carraway HE, Malkaram SA, Cen Y, Shatnawi A, Fan J, Ali HEA, Abd Elmageed ZY, Buttolph T, Denvir J, Primerano DA, Fandy TE. Carraway HE, et al. Among authors: shatnawi a. Sci Rep. 2020 Jun 25;10(1):10325. doi: 10.1038/s41598-020-67170-8. Sci Rep. 2020. PMID: 32587297 Free PMC article.

10

Author Correction: Activation of SIRT6 by DNA hypomethylating agents and clinical consequences on combination therapy in leukemia.

Carraway HE, Malkaram SA, Cen Y, Shatnawi A, Fan J, Ali HEA, Abd Elmageed ZY, Buttolph T, Denvir J, Primerano DA, Fandy TE. Carraway HE, et al. Among authors: shatnawi a. Sci Rep. 2020 Sep 22;10(1):15386. doi: 10.1038/s41598-020-70622-w. Sci Rep. 2020. PMID: 32968125 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

32 results

Search Page

Filters